A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan

Table 6 Cox regression analysis for time to skin rash

	nmCRPC				mCRPC				mCNPC
	HR	95% CI (Lower)	95% CI (Upper)	p-value	HR	95% CI (Lower)	95% CI (Upper)	p-value	HR	95% CI (Lower)	95% CI (Upper)	p-value
Age group at the index date
18–49	–				1.36	0.16	11.48	0.7760	–
50–59	1			Ref	1			Ref	1			Ref
60–69	1.71	1.03	2.84	0.0395	1.17	0.50	2.76	0.7211	0.94	0.40	2.20	0.8805
70–79	2.00	1.22	3.29	0.0062	1.54	0.66	3.57	0.3162	0.97	0.42	2.21	0.9338
80–89	2.69	1.63	4.42	< 0.0001	1.93	0.83	4.48	0.1273	1.35	0.59	3.09	0.4747
90+	3.68	2.16	6.25	< 0.0001	3.83	1.49	9.82	0.0052	2.48	1.00	6.18	0.0508
Baseline PSA
Median PSA	1.29	1.03	1.62	0.028	1.24	0.92	1.69	0.163	1.37	0.88	2.14	0.163
BMI
BMI < 18.5	0.50	0.38	0.66	< 0.0001	0.49	0.33	0.74	0.0006	0.67	0.41	1.10	0.1130
18.5 ≤ BMI < 25	Ref
BMI ≥ 25	0.89	0.68	1.16	0.3830	1.01	0.70	1.46	0.9569	0.97	0.64	1.47	0.8730
Allergy and hypersensitivity	1.89	1.37	2.59	< 0.0001	2.26	1.51	3.40	< 0.0001	1.84	1.09	3.12	0.023

In the Cox regression for PSA, < median PsA was considered as reference; in the Cox regression for BMI, a normal weight (18.5 ≤ BMI < 25) was considered as reference; in the Cox regression for allergy and hypersensitivity, non-history (no allergy or hypersensitivity) was considered as reference
BMI Body mass index, CI Confidence interval, HR Hazard ratio, mCNPC Metastatic castration-naïve prostate cancer, mCRPC Metastatic castration-resistant prostate cancer, nmCRPC Non-metastatic castration-resistant prostate cancer, PSA Prostate-specific antigen, Ref Reference level, RP Radical prostatectomy, RT Radiotherapy

ISSN: 1471-2490